



## **Ventripoint Attends 23<sup>rd</sup> Annual Canadian Echo Weekend and Grants Stock Options**

**Toronto, Ontario – The Newswire – April 20, 2021** - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) attended the 23<sup>rd</sup> Annual Canadian Echo Weekend – 2021 Digital Edition, which was organized by the Canadian Society of Echocardiography (CSE).

Ventripoint participated as a sponsor for this year's conference and received a high profile. The Company had a prominent booth in the virtual exhibit hall and showcased a demo video, VMS+3.0 clinical materials, a signup sheet for potential research collaborators, and an advertisement for the next webinar to be held in May.

Outcomes from the weekend were:

1. A new application was identified, and a potential lead investigator was engaged,
2. Cardiologists signed up for the forthcoming webinar entitled "Remembering the forgotten ventricle – exploring the benefits of accurate and reliable measurements",
3. The Company was able to advance discussions with key cardiologists to conduct clinical evaluations, where the VMS can uniquely provide better and more timely information. These studies will be initiated once echocardiography services can fully re-open and resume normal operations.

The CSE is a non-profit organization comprised of 2,000 cardiovascular professions and strives to promote high quality echocardiographic services across Canada. This year's virtual conference had an attendance of over 1,100 delegates that included cardiologists, internists, sonographers, and trainees from across the country and outside Canada.

In other news, on April 12, 2021 the Company granted 100,000 stock option grants to a consultant and 100,000 option grants to an employee. The stock option grants vested immediately and have an exercise price of \$.50. After this grant, the Company has 836,250 options remaining for future grants.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile

and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
[gadams@venripoint.com](mailto:gadams@venripoint.com)  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.